2. Neurological Disease

Neurological Disease

Neurological Disease

Related Products

PDF 88.0 MB

A range of neurological disorders, including epilepsy and dystonia, may involve dysfunctional intracortical inhibition, and may respond to treatments that modify it. Parkinson’s is a neurodegenerative disease characterized by increased activity of GABA in basal ganglia and the loss of dopamine in nigrostriatum, associated with rigidity, resting tremor, gait with accelerating steps, and fixed inexpressive face. Neurological deficits, along with neuromuscular involvement, are characteristic of mitochondrial disease, and these symptoms can have a dramatic impact on patient quality of life. Neurological features may be manifold, ranging from neural deafness, ataxia, peripheral neuropathy, migraine, seizures, stroke‐like episodes and dementia and depend on the part of the nervous system affected.

Cat. No. Product Name CAS No. Purity Chemical Structure
  • HY-107944
    Chlorphenesin carbamate 886-74-8 99.92%
    Chlorphenesin carbamate is a centrally acting skeletal muscle relaxant, as well as a derivate of Chlorphenesin (HY-A0133). Chlorphenesin carbamate can be used for the research of pain and discomfort related to skeletal muscle trauma and inflammation. Chlorphenesin carbamate is a selective blocker of polysynaptic pathways at the spinal and supra-spinal levels. Antinociceptive effect.
    Chlorphenesin carbamate
  • HY-107969
    Haloperidol decanoate 74050-97-8 99.67%
    Haloperidol decanoate is a depot preparation of haloperidol, a commonly used butyrophenone derivative with antipsychotic activity. Haloperidol decanoate can increase the striatal D2 receptor in rat. Haloperidol decanoate can improve conditions of psychoses (mainly schizophrenia). Haloperidol decanoate can lead to increased accumulation of the dopamine metabolites homo-vanillic acid. Haloperidol decanoate can reduce intestinal transport, increase gastric emptying and reduce acid output in rat model.
    Haloperidol decanoate
  • HY-108319
    DPP-IV-IN-2 136259-18-2 ≥98.0%
    DPP-IV-IN-2 is an inhibitor of both dipeptidyl peptidase IV (DPIV) and DP8/9 with IC50s of 0.1 and 0.95 μM, respectively.
    DPP-IV-IN-2
  • HY-108497
    L-803087 217480-26-7 ≥98.0%
    L-803087 is a potent and selective somatostatin sst4 receptor agonist with a Ki of 0.7 nM. L-803087 is >280-fold higher than other somatostatin receptors. L-803087 facilitates AMPA-mediated hippocampal synaptic responses in vitro and increases kainate-induced seizures in mice.
    L-803087
  • HY-108512
    PD 144418 154130-99-1 98.32%
    PD 144418 is a highly affinity, potent and selective sigma 1 (σ1) receptor ligand (Ki values of 0.08 nM and 1377 nM for σ1 and σ2 respectively). PD 144418 devoids of any significant affinity for other receptors, ion channels and enzymes. PD 144418 shows potential antipsychotic activity.
    PD 144418
  • HY-108586
    NS3623 343630-41-1 ≥99.0%
    NS3623 is an activator of human ether-a-go-go-related gene (hERG1/KV11.1) potassium channels. NS3623 activates the IKr and Ito currents and has antiarrhythmic effect. NS3623 has a dual mode of action, being an inhibitor of hERG1 channels.
    NS3623
  • HY-108592
    UCL 2077 918311-87-2 98.91%
    UCL 2077 is a selective slow-afterhyperpolarization (sAHP) channel blocker (IC50 = 500 nM in hippocampal neurons in culture), having minimal effects on Ca2+ channels, action potentials, input resistance and the medium after hyperpolarization. UCL 2077 is also a subtype-selective blocker of the epilepsy associated KCNQ channels.
    UCL 2077
  • HY-109538
    Secretin (swine) 17034-35-4 99.16%
    Secretin (swine), a neuroendocrine hormone, is the first hormone to be identifie and is secreted by S cells that are localized primarily in the mucosa of the duodenum. Secretin also is a 27-amino acid peptide, which acts on secretin receptors. Secretin is expressed by cells in all mature enteroendocrine cell subsets and can be prompted by fatty acids. Secretin stimulates the secretion of pancreatic water and bicarbonate. Secretin exerts various effects in organs, can be used for the research of digestive system, central nervous system and energy metabolism.
    Secretin (swine)
  • HY-110160
    Pozanicline dihydrochloride 161416-61-1 ≥99.0%
    Pozanicline dihydrochloride (ABT-089 dihydrochloride) is an orally bioavailable nicotinic acetylcholine receptor (nAChR) agonist with a Ki of 16.7 nM for binding to [3H]cytisine sites. Pozanicline is an α4β2-selective nAChR agonist, which binds to rat brain α4β2 nAChR with a Ki of 17 nM while binding to α7 nAChR is insignificant.
    Pozanicline dihydrochloride
  • HY-110175
    CX614 191744-13-5 99.94%
    CX614 is a positive variant modulator of AMPA receptors that enhances excitatory postsynaptic potentials (amplitude and duration) by blocking and slowing the inactivation of responses to glutamate and automatically evokes excitatory postsynaptic currents in neuronal cultures. CX614 can be used in the study of psychiatric disorders such as depression.
    CX614
  • HY-110263
    EML 425 1675821-32-5 98.04%
    EML425 is a potent and selective CREB binding protein (CBP)/p300 inhibitor with IC50s of 2.9 and 1.1 μM, respectively.
    EML 425
  • HY-111474
    Para-aminoblebbistatin 2097734-03-5 99.90%
    Para-aminoblebbistatin is the inhibitor for myosin II. Para-aminoblebbistatin inhibits the ATPase activity of myosin II, thereby blocking the formation and contraction of the actin-myosin network. Para-aminoblebbistatin is a non-fluorescent and photostable Blebbistatin (HY-13813) derivative.
    Para-aminoblebbistatin
  • HY-113421
    Linoleoyl ethanolamide 68171-52-8 ≥98.0%
    Linoleoyl ethanolamide (Linoleic acid monoethanolamide) is classified as a fatty acid ethanolamide. Linoleoyl ethanolamide only weakly binds G-protein-coupled cannabinoid receptors of type-1（CB1）and CB2 receptors, and inhibits the binding of [3H]CP-55,940 with Kis of 10 and 25 μM, respectively. Linoleoyl ethanolamide is 4-fold less potent than anandamide at causing catalepsy in mice and it does not prolong sleep time.
    Linoleoyl ethanolamide
  • HY-115726
    FRM-024 2085780-87-4 99.45%
    FRM-024 is a potent CNS-penetrant gamma secretase modulator for familial Alzheimer’s disease.
    FRM-024
  • HY-116530
    9-Cyclopentyladenine monomethanesulfonate 189639-09-6 99.16%
    9-Cyclopentyladenine monomethylsulfonate (9-CP-Ade mesylate) is a stable non-competitive adenylate cyclase inhibitor with cell permeable properties.
    9-Cyclopentyladenine monomethanesulfonate
  • HY-116800
    FR194921 202646-80-8 98.10%
    FR194921 is a potent, selective and orally active and cross the blood-brain barrier Adenosine A1 antagonist with Ki value of 6.6, 5400 nM for A1, A2A, respectively. FR194921 shows cognitive-enhancing and anxiolytic activity.
    FR194921
  • HY-116941
    A-381393 726174-00-1 99.92%
    A-381393 is a potent, selective, brain penetrate dopamine D4 receptor antagonist, with Kis of 1.5, 1.9 and 1.6 nM for human dopamine D4.4, D4.2, and D4.7 receptor, respectively, >2700-fold selectivity over D1, D2, D3 and D5 dopamine receptors. A-381393 shows moderate affinity for 5-HT2A (Ki, 370 nM).
    A-381393
  • HY-117482
    BPN-15606 1914989-49-3 99.96%
    BPN-15606 is a highly potent, orally active γ-secretase modulator (GSM), attenuates the production of Aβ42 and Aβ40 by SHSY5Y neuroblastoma cells with IC50 values of 7 nM and 17nM, respectively. BPN-15606 lowers Aβ42 and Aβ40 levels in the central nervous system of rats and mice. BPN-15606 has acceptable PK/PD properties, including bioavailability, half-life, and clearance.
    BPN-15606
  • HY-117541
    Glycyl-glutamine 13115-71-4 ≥98.0%
    Glycyl-glutamine (Glycyl-L-glutamine), as a enzymatic cleavage product of β-endorphin, is apparently an endogenous antagonist of beta-endorphin(1-31) in several systems. Glycyl-glutamine (Glycyl-L-glutamine) is an activate and stable glutamine-containing neuropeptide over glutamine (Gln).
    Glycyl-glutamine
  • HY-118785
    MSP-3 1820968-63-5 98.53%
    MSP-3 is a potent TRPV1 agonist, with an EC50 of 0.87 μM. MSP-3 exhibits neuroprotective and antinociceptive effects.
    MSP-3
Cat. No. Product Name / Synonyms Application Reactivity